Sarcoidosis

1. High-Yield Summary

• Multisystem Granulomatous Infiltration: Sarcoidosis is an idiopathic systemic inflammatory disorder characterized by non-caseating epithelioid granulomas, with musculoskeletal manifestations identified in 5% to 15% of patients across osseous (1–13%), articular (10–35%), and neuromuscular (1–5%) compartments.
• The Acute Triad of Löfgren Syndrome: Acute presentation featuring bilateral ankle periarthritis or tenosynovitis, erythema nodosum, and bilateral hilar lymphadenopathy (BHL); carries an excellent clinical prognosis with greater than 90% spontaneous resolution within 12 to 24 months.
• Osseous Hallmarks (Perthes-Jüngling Disease): Chronic skeletal involvement predominantly targets the middle and distal phalanges of the hands and feet, producing pathognomonic “lace-like” or “honeycomb” trabecular osteolysis without periosteal new bone formation.
• The Orthopaedic Mimic Trap: Primary skeletal sarcoidosis frequently presents as an isolated, expansile osteolytic lesion or palpable soft-tissue pseudo-tumor without antecedent pulmonary history; over 80% are initially misdiagnosed as metastatic carcinoma, multiple myeloma, or fungal/mycobacterial osteomyelitis. Biopsy demonstrating non-caseating granulomas with negative acid-fast and fungal stains halts inappropriate radical oncologic resection.
• Evidence-Based Medical Hierarchy: First-line medical therapy for symptomatic bone and joint lesions is oral corticosteroids (prednisone 20–40 mg/day). Disease-modifying antirheumatic drugs (primarily methotrexate) and anti-tumor necrosis factor-alpha (anti-TNF-α) biologics (infliximab, adalimumab) provide refractory disease control and arrest progressive osteolysis in over 75% to 80% of patients. Operative intervention is strictly limited to biopsy, fracture stabilization, or end-stage arthroplasty.

2. Anatomy

Musculoskeletal sarcoidosis can involve any anatomical compartment of the locomotive system, displaying characteristic topographical patterns across osseous, articular, and muscular structures:

Osseous Topography & Microarchitecture

Osseous lesions exhibit a marked predilection for the small tubular bones of the hands and feet (accounting for 80% to 90% of skeletal cases), followed by the axial spine (thoracic and lumbar vertebral bodies), pelvis, ribs, and proximal metadiaphyses of long bones (femur, tibia, and humerus). Pathologically, granulomatous infiltration begins in the richly vascularized hematopoietic red marrow of cancellous bone. Expanding non-caseating granulomas drive progressive resorption of trabecular architecture via osteoclastic recruitment. As cancellous trabeculae are excavated, the cortex undergoes endosteal scalloping, tunneling, and remodeling, producing the classic reticular and honeycomb architecture. Unlike osteomyelitis or primary bone tumors, periosteal reaction is conspicuously absent in osseous sarcoidosis unless secondary pathologic microfracture supervenes.

Articular & Periarticular Compartments

Joint involvement manifests in two distinct anatomic patterns:

• Acute Periarticular Disease: Predominantly targets the tibiotalar and subtalar joints, midfoot, and knees. The underlying pathology is intense periarticular subcutaneous inflammation, tenosynovitis (peroneal, posterior tibial, and extensor tendon sheaths), and ligamentous edema rather than destructive intra-articular synovitis.
• Chronic Granulomatous Synovitis: Direct granulomatous infiltration of the synovial membrane, joint capsule, and subchondral bone plate, most commonly involving the knees, ankles, wrists, and metacarpophalangeal (MCP) joints. Persistent synovial proliferation leads to articular cartilage fibrillation, joint space narrowing, subchondral cyst formation, and secondary degenerative joint disease.

Muscular & Fascial Architecture

Skeletal muscle involvement is categorized into three anatomical presentations:

• Chronic Myopathy: Symmetrical, indolent interstitial granulomatous infiltration of proximal muscle groups (quadriceps femoris, gluteal musculature, biceps brachii, and deltoid), leading to endomysial fibrosis and myofiber atrophy.
• Acute Myositis: Diffuse inflammatory edema and lymphocytic infiltration within muscle bellies, presenting with acute compartment fullness, severe tenderness, and functional paresis.
• Nodular Myopathy (Pseudo-Tumor): Well-demarcated, dense granulomatous masses encapsulated within muscle fascial envelopes, frequently mistaken for soft-tissue sarcomas.

Neurovascular Danger Zones & Compression Corridors

Surgeons and clinicians must account for critical neurovascular relationships when evaluating and managing musculoskeletal lesions:

• Digital Corridors: In sarcoid dactylitis, expansile phalangeal remodeling and granulomatous flexor tenosynovitis compress the digital neurovascular bundles running palmar to Cleland and Grayson ligaments, predisposing to digital ischemia or dysesthesia.
• Carpal & Tarsal Tunnels: Proliferative tenosynovitis within the fibro-osseous carpal canal results in secondary median nerve compression (carpal tunnel syndrome), while posterior tibial tenosynovitis precipitates tarsal tunnel syndrome.
• Spinal Neural Corridors: Granulomatous infiltration of the anterior vertebral body can breach the posterior longitudinal ligament, forming an epidural granulomatous phlegmon that encroaches on the spinal canal and neural foramina, compressing the thecal sac, spinal cord, or exiting nerve roots.

3. Pathogenesis

The pathogenesis of sarcoidosis represents an antigen-driven, cell-mediated hypersensitivity cascade occurring in genetically predisposed hosts possessing specific human leukocyte antigen (HLA) class II alleles (such as HLA-DRB1*11 and HLA-DRB1*15) and butyrophilin-like 2 (BTNL2) gene polymorphisms. The cascade initiates when an unidentified persistent environmental or infectious trigger (such as mycobacterial catalase-peroxidase KatG, Propionibacterium acnes antigens, or inorganic microparticulates) is processed by dendritic cells and alveolar macrophages.

Antigen presentation to naïve CD4+ T helper cells induces a vigorous T-helper 1 (Th1) and Th17 immune polarization, accompanied by massive local secretion of interferon-gamma (IFN-γ), interleukin-2 (IL-2), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α). TNF-α serves as the indispensable master cytokine for granuloma architecture, driving macrophage differentiation into specialized epithelioid histiocytes, fusion into multinucleated Langhans giant cells, and recruitment of circulating monocytes to sustain the granulomatous core.

Histologically, the hallmark of the disease is the discrete, non-caseating epithelioid cell granuloma. The central core comprises epithelioid histiocytes and multinucleated giant cells containing cytoplasmic inclusions such as star-shaped asteroid bodies, basophilic laminated Schaumann bodies, and calcium carbonate conchoid bodies. The core is enveloped by a peripheral mantle of CD4+ T lymphocytes with scattered CD8+ T cells and fibroblasts, without central coagulative necrosis.

In osseous tissue, macrophages and T lymphocytes within the granuloma synthesize receptor activator of nuclear factor kappa-B ligand (RANKL), interleukin-1 (IL-1), and TNF-α. This localized cytokine surge triggers intense osteoclastogenesis, stimulating mature osteoclasts to excavate cancellous bone trabeculae. Concurrently, epithelioid macrophages express CYP27B1 (1-alpha-hydroxylase), converting 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D (calcitriol) independent of parathyroid hormone (PTH) feedback regulation. This ectopic enzymatic activity drives systemic hypercalcemia and hypercalciuria, accelerating systemic osteopenia.

4. Natural History

Sarcoidosis demonstrates marked geographic and ethnic variation, with global prevalence ranging from 10 to 40 per 100,000 individuals. The highest prevalence occurs in Northern European populations (up to 60 per 100,000 in Scandinavian cohorts) and in African Americans (35 to 45 per 100,000). African American individuals exhibit a threefold to fourfold higher disease lifetime risk, greater disease severity, and a significantly higher incidence of chronic, relapsing, and extrapulmonary skeletal disease compared to Caucasian populations. The primary diagnostic peak occurs between 20 and 40 years of age, with a secondary incidence peak observed in females older than 50 years.

Musculoskeletal involvement is clinically recognized in 5% to 15% of all sarcoidosis cohorts, although post-mortem and advanced imaging series demonstrate subclinical involvement in up to 30% of patients. Osseous involvement occurs in 1% to 13% of cases, articular involvement in 10% to 35%, and symptomatic myopathy in 1% to 5%.

The natural history diverges sharply according to clinical presentation:

• Acute Self-Limiting Form (Löfgren Syndrome): Displays an extraordinarily benign trajectory. Spontaneous complete clinical resolution occurs in 85% to 90% of patients within 12 to 24 months, with recurrence rates below 10% and negligible long-term articular morbidity.
• Chronic Progressive Musculoskeletal Sarcoidosis: Typically associated with multiorgan chronic disease, including lupus pernio, chronic uveitis, pulmonary fibrosis, and cardiac involvement. Chronic osseous and articular lesions display an indolent, refractory course; spontaneous radiographic resolution is documented in fewer than 15% of cases. Left untreated, progressive trabecular osteolysis leads to cortical destruction, joint subluxation, pathologic fractures, and permanent functional impairment.

5. Clinical Presentation

History

A systematic clinical history must differentiate between acute inflammatory flares and chronic insidious destruction:

• Constitutional Symptoms: Debilitating fatigue (reported in up to 70% of patients), low-grade evening fevers, malaise, night sweats, and unintentional weight loss.
• Articular Symptoms: Acute, intense, bilateral ankle or knee pain accompanied by rapid soft-tissue swelling that impairs ambulation, typically with minimal preceding trauma. In chronic arthropathy, symptoms evolve into symmetric morning stiffness and persistent joint aching resembling seronegative rheumatoid arthritis.
• Osseous Pain & Dactylitis: Chronic, deep-seated aching bone pain localized to the digits, spine, pelvis, or extremities, frequently worse at night or during weight-bearing. Patients with digital involvement report progressive, painless or tender swelling of the fingers or toes (“sausage digits”).
• Myopathic Symptoms: Symmetrical proximal muscle weakness manifested as difficulty climbing stairs, rising from a low chair, or lifting objects overhead, or the discovery of an expanding, painless muscular mass.
• Review of Systems: Exertional dyspnea or non-productive cough (pulmonary parenchymal disease), red or painful eyes and visual disturbances (uveitis), skin lesions or subcutaneous nodules, and palpitations, presyncope, or syncope (cardiac conduction abnormalities).

Physical Exam

Physical examination must systematically evaluate dermatologic, articular, osseous, and neuromuscular structures using standardized diagnostic maneuvers:

6. Imaging and Diagnostic Studies

Accurate diagnosis requires multimodality imaging corroborated by laboratory biomarkers and mandatory histopathologic tissue confirmation:

Plain Radiography

Standard plain radiography of the hands and feet serves as the primary screening examination for skeletal sarcoidosis. Radiographic abnormalities are classified into three classical patterns:

• Lace-like / Permeative Pattern (Pathognomonic): Reticular tunneling and resorption of cancellous trabeculae within the middle and distal phalanges, accompanied by cortical thinning and remodeling with preserved periosteal margins.
• Cystic / Punched-Out Pattern: Discrete, well-circumscribed, round or oval radiolucent osteolytic defects located in the subchondral bone or metaphysis without surrounding reactive sclerosis.
• Diffuse Destructive Pattern: Extensive cortical violation, pathological microfractures, articular surface collapse, and acro-osteolysis resulting in digital shortening.

Computed Tomography (CT)

High-resolution thin-slice bone CT precisely defines trabecular micro-architecture, reveals subtle endosteal scalloping, and verifies cortical integrity. CT confirms the absence of chondroid ring-and-arc or osteoid matrix mineralization, effectively ruling out chondrosarcoma and osteosarcoma. In spinal lesions, CT delineates anterior vertebral endplate erosions and osteolysis while assessing spinal canal compromise.

Magnetic Resonance Imaging (MRI)

MRI provides exceptional sensitivity (exceeding 95%) for identifying marrow infiltration, occult bone lesions, synovitis, and soft-tissue masses. The signal characteristics across musculoskeletal tissues include:

• Osseous Marrow Infiltration: Low signal intensity on T1-weighted images replacing normal hyperintense fatty marrow; marked high signal intensity on T2-weighted and Short Tau Inversion Recovery (STIR) images reflecting inflammatory edema; and intense, homogeneous or heterogeneous enhancement following intravenous gadolinium administration.
• Nodular Muscular Sarcoidosis: Displays the pathognomonic “dark star” sign on axial T2-weighted images—a central star-shaped zone of low signal intensity representing dense collagenous fibrosis surrounded by a peripheral rim of high-signal inflammatory edema and intense peripheral contrast enhancement.
• Articular Synovitis: Nodular or diffuse synovial thickening with intermediate T1 and low-to-intermediate T2 signal due to dense granulomatous cellularity and fibrous tissue, showing avid enhancement.

18F-FDG PET/CT

Whole-body fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (18F-FDG PET/CT) represents the most sensitive whole-body imaging modality for assessing disease extent and metabolic activity. Sarcoid granulomas exhibit intense glucose hypermetabolism, with maximum standardized uptake values (SUVmax) typically ranging from 6.0 to 15.0. 18F-FDG PET/CT is invaluable for identifying clinically occult active osseous or cardiac sites, guiding biopsy to the most hypermetabolic target, and objectively quantifying treatment response.

Laboratory Biomarkers & Histopathology

Laboratory testing supports the diagnosis and monitors systemic organ involvement:

• Serum Angiotensin-Converting Enzyme (ACE): Elevated in approximately 60% of active cases due to production by epithelioid granuloma cells. However, serum ACE exhibits poor sensitivity and specificity (frequently normal in up to 40% of confirmed osseous cases) and is not diagnostic in isolation.
• Calcium Metabolism Panel: Hypercalcemia occurs in 10% to 15% of patients, and 24-hour hypercalciuria (>300 mg/24 hours) is present in 30% to 40%, accompanied by elevated serum 1,25-dihydroxyvitamin D and suppressed PTH levels.
• Inflammatory Markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated during acute flares and normalize following clinical remission.
• Histopathologic Tissue Biopsy (Gold Standard): Mandatory in primary musculoskeletal presentations or atypical diagnostic settings. Core-needle or open surgical biopsy demonstrates discrete, uniform, non-caseating epithelioid cell granulomas with multinucleated giant cells and a sparse rim of lymphocytes. Special histochemical staining is strictly mandatory: Ziehl-Neelsen or auramine-rhodamine for acid-fast bacilli (AFB) and Grocott methenamine silver (GMS) or periodic acid-Schiff (PAS) for fungal organisms must be negative, and mycobacterial/fungal tissue cultures must show no growth.

7. Classification

Musculoskeletal sarcoidosis is classified based on anatomical compartment, radiographic morphology, and clinical course, which directly dictate therapeutic strategy and surgical precautions:

8. Treatment

Medical & Nonoperative Management

Medical pharmacotherapy represents the primary therapeutic foundation for musculoskeletal sarcoidosis, executed in a tiered multidisciplinary framework:

• First-Line Corticosteroid Therapy: Oral prednisone is indicated for symptomatic osseous sarcoidosis, acute myositis, and debilitating polyarthritis. Initial dosing is 0.5 to 0.75 mg/kg/day (typically 20 to 40 mg daily) for 4 to 8 weeks, followed by a gradual taper over 6 to 12 months targeting a maintenance dose below 7.5 to 10 mg daily. High initial response rates (70% to 80%) are observed in acute arthritis and myopathy.
• Second-Line DMARD Therapy (Steroid-Sparing): Indicated for corticosteroid dependence, frequent relapsing flares, corticosteroid toxicity, or chronic progressive osseous lesions. Methotrexate (15 to 25 mg once weekly orally or subcutaneously with concurrent daily folic acid 1 mg) is the preferred second-line agent, inducing remission or stability in 65% to 75% of patients. Alternative agents include azathioprine (1.5 to 2.5 mg/kg/day), leflunomide (20 mg/day), or hydroxychloroquine (200 to 400 mg/day, particularly effective for cutaneous and periarticular disease; requires annual retinal screening).
• Third-Line Biologic Therapy (Anti-TNF-α Monoclonal Antibodies): Indicated for refractory osseous sarcoidosis, axial spinal lesions, or disabling chronic myopathy failing conventional DMARDs. Infliximab (5 mg/kg intravenously at weeks 0, 2, and 6, followed by maintenance infusions every 6 to 8 weeks) or Adalimumab (40 mg subcutaneously every 1 to 2 weeks) achieve objective clinical and radiographic remission in 75% to 85% of treatment-refractory patients. Mandatory pre-treatment screening includes interferon-gamma release assay (IGRA) for latent tuberculosis, hepatitis serologies, and echocardiography.
• Nonoperative Biomechanical Support: Buddy-taping or custom thermoplastic splinting of affected digits during active sarcoid dactylitis to prevent pathologic fracture; structured low-impact physical therapy to preserve joint range of motion and counteract muscle atrophy; and bone health protection with bisphosphonates (alendronate 70 mg weekly or zoledronic acid 5 mg IV annually) in patients requiring prolonged corticosteroid therapy, accompanied by serial 24-hour urine calcium and DEXA monitoring.

Operative Management

The primary goals of orthopaedic surgery in musculoskeletal sarcoidosis are achieving definitive histological diagnosis with minimal tissue disruption, stabilizing pathologic fractures, relieving mechanical neural compression, and restoring mobility in joints with end-stage secondary arthrosis:

• Diagnostic Biopsy: Core-needle biopsy (under CT or ultrasound guidance) or meticulous open incisional biopsy. The biopsy tract must be oriented directly along the planned incision line of any potential future oncologic resection. Frozen section is utilized to confirm viable diagnostic material, and specimens must be divided immediately for formal histopathology, AFB stains, fungal stains, and microbiology cultures.
• Pathologic Fracture Stabilization: Open reduction and rigid internal fixation utilizing low-profile pre-contoured locking plates or intramedullary nails. Due to severe focal osteopenia and bone voids created by granulomatous resorption, fixation should be augmented with polymethylmethacrylate (PMMA) bone cement or structural bone graft substitutes to ensure load-bearing stability.
• Digital Arthrodesis: Indicated for painful, flail, or destructively subluxated interphalangeal joints resulting from advanced Type III Jüngling dactylitis failing medical suppression. Low-profile headless compression screws or tension-band wire constructs achieve reliable fusion.
• Decompression of Entrapment Neuropathies: Open carpal tunnel release, cubital tunnel decompression, or spinal decompressive laminectomy for granulomatous masses producing progressive neurological deficits.
• Total Joint Arthroplasty (TJA): Total knee, hip, or shoulder arthroplasty for end-stage secondary osteoarthritis resulting from chronic granulomatous joint destruction. Surgery must be scheduled strictly during periods of medically confirmed disease quiescence.

Indications & Contraindications

Surgical indications and contraindications require rigorous clinical thresholds:

• Absolute Surgical Indications:
  • Undiagnosed destructive bone or soft-tissue mass where primary musculoskeletal malignancy, metastatic carcinoma, or mycobacterial/fungal osteomyelitis cannot be definitively excluded.
  • Progressive motor neurological deficit, cauda equina syndrome, or myelopathy resulting from epidural granulomatous masses or vertebral collapse.
  • Displaced or impending pathologic fracture in weight-bearing long bones (Mirels score of 8 or greater).
  • Severe, disabling, end-stage secondary joint destruction refractory to comprehensive medical immunosuppression.
• Relative Surgical Indications: Chronic, recalcitrant digital subluxation with severe mechanical impairment; localized compressive tenosynovitis with impending flexor tendon rupture.
• Contraindications: Performing wide or radical oncologic resection prior to histological confirmation; elective surgical intervention during acute systemic sarcoid flares with active cardiac or severe pulmonary involvement; and operating in the presence of uncharacterized active systemic infection.

9. Outcome

Clinical outcomes in musculoskeletal sarcoidosis correlate closely with anatomical subtype and timeliness of targeted immunosuppression:

• Löfgren Syndrome: Greater than 85% to 90% of patients experience complete, spontaneous resolution of periarticular ankle arthritis and erythema nodosum within 12 to 24 months, with preserved long-term joint function and normal patient-reported outcome measures.
• Osseous Sarcoidosis: Large cohort studies demonstrate that combined therapy with corticosteroids and DMARDs or anti-TNF-α biologics achieves symptomatic stability or improvement in 73% of patients, with arrest of progressive osteolytic destruction in over 70%. Radiographic bone remineralization and complete healing of permeative lesions occur in approximately 30% to 50% of responsive patients.
• Total Joint Arthroplasty Survivorship: In quiescent disease, total joint arthroplasty yields significant improvements in validated patient-reported outcome measures (WOMAC, Knee Society Scores, ASES) comparable to non-sarcoid osteoarthritis cohorts. However, patients maintained on chronic corticosteroids and immunosuppressive biologics exhibit higher rates of surgical site complications, wound delayed healing, and periprosthetic joint infection, requiring meticulous perioperative optimization.

10. Complications

Complications span intraoperative technical hazards, early immunosuppression-related adverse events, and late structural musculoskeletal failures:

11. Pearls and Pitfalls

Navigating musculoskeletal sarcoidosis requires specialized clinical vigilance:

• The Great Clinical Mimic: Always consider sarcoidosis in the differential diagnosis of a middle-aged patient presenting with multiple “punched-out” osteolytic lesions, preserved joint spaces, and minimal periosteal reaction, particularly when chest imaging demonstrates incidental bilateral hilar lymphadenopathy.
• Examine the Ankles in Erythema Nodosum: Acute bilateral ankle periarthritis combined with erythema nodosum in a young adult is Löfgren syndrome until proven otherwise; it requires conservative anti-inflammatory management rather than invasive arthroscopic debridement or synovial biopsy.
• Mandatory Histochemical Staining Protocol: Never accept a pathology report of “granulomatous inflammation” without verifying negative Ziehl-Neelsen (AFB) and Grocott silver (GMS) stains and negative mycobacterial/fungal cultures. Administering high-dose corticosteroids or anti-TNF-α biologics to an undiagnosed tuberculosis or fungal osteomyelitis causes fulminant, catastrophic systemic dissemination.
• Screen for Silent Hypercalciuria: Serum calcium may remain deceptively normal while 24-hour urine calcium is markedly elevated due to autonomous 1-alpha-hydroxylase activity in granulomas. Screen all patients with 24-hour urine calcium to prevent silent nephrolithiasis and irreversible renal calcinosis.
• Avoid Radical Resection of Muscle Pseudo-Tumors: Nodular muscular sarcoidosis can mimic soft-tissue sarcomas clinically and on MRI. Performing a percutaneous core biopsy confirming non-caseating granulomas avoids an unnecessary, disabling radical compartmental excision.
• Never Exclude Sarcoidosis on a Normal Serum ACE: Up to 40% of patients with biopsy-proven musculoskeletal sarcoidosis have normal serum ACE levels. ACE carries poor diagnostic sensitivity and must never be used as a definitive rule-out test.
• Mandatory Cardiac & Ocular Screening: When musculoskeletal sarcoidosis is confirmed, immediately order a resting 12-lead ECG, echocardiogram, and slit-lamp ophthalmologic exam. Occult cardiac granulomatous infiltration is the primary driver of sudden arrhythmogenic death in sarcoidosis.

12. Controversy

Early Biologic Induction vs. Step-Wise Conventional DMARD Escalation

Traditional rheumatologic guidelines advocate a strict step-wise treatment escalation: nonsteroidal anti-inflammatory drugs, followed by high-dose corticosteroids, followed by conventional synthetic DMARDs (methotrexate, azathioprine), reserving anti-TNF-α biologics strictly for refractory failure. However, osseous sarcoidosis is notoriously recalcitrant to corticosteroids alone, frequently necessitating prolonged supraphysiologic doses that cause debilitating osteonecrosis, steroid osteoporosis, and metabolic toxicity. Growing orthopaedic and rheumatologic evidence suggests that early induction with anti-TNF-α biologics (such as infliximab or adalimumab) in patients with structural osseous lesions rapidly suppresses granulomatous osteoclastogenesis, promotes cortical remineralization, and prevents structural bone collapse while substantially reducing cumulative corticosteroid exposure.

Management of Asymptomatic Skeletal Lesions Detected on 18F-FDG PET/CT

The widespread clinical adoption of whole-body 18F-FDG PET/CT and whole-body MRI has dramatically increased the detection of clinically occult, asymptomatic osseous lesions in patients undergoing staging for pulmonary or ocular sarcoidosis. Considerable debate persists regarding whether asymptomatic hypermetabolic bone lesions warrant aggressive systemic immunosuppression to prevent future structural bone loss, or whether expectant observation with serial radiographic surveillance is safe in non-weight-bearing anatomical locations.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Smedslund G, Kotar AM, Uhlig T. Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments. Rheumatol Int. 2022. doi:10.1007/s00296-022-05171-8 [Level I: Systematic Review / Meta-Analysis]
• Sparks JA, McSparron JI, Shah N et al. Osseous sarcoidosis: clinical characteristics, treatment, and outcomes–experience from a large, academic hospital. Semin Arthritis Rheum. 2014. doi:10.1016/j.semarthrit.2014.07.003 [Level IV: Clinical Case Series / Cohort Study]
• Moore SL, Teirstein AE. Musculoskeletal sarcoidosis: spectrum of appearances at MR imaging. Radiographics. 2003. doi:10.1148/rg.236025172 [Level II: Comparative Study / Decision Analysis]
• Bechman K, Christidis D, Walsh S et al. A review of the musculoskeletal manifestations of sarcoidosis. Rheumatology (Oxford). 2018. doi:10.1093/rheumatology/kex317 [Level IV: Clinical Case Series / Cohort Study]
• Anakwenze OA, Kancherla V, Hatch M et al. Primary musculoskeletal sarcoidosis. Orthopedics. 2010. doi:10.3928/01477447-20100329-07 [Level IV: Clinical Case Series / Cohort Study]

15. Master Class Pro-Tip

When evaluating an isolated, expansile osteolytic lesion of the hand, spine, or pelvis in an adult without known malignancy, never proceed directly to radical resection without a disciplined histological pause. Primary musculoskeletal sarcoidosis is one of the classic great orthopaedic masqueraders, frequently mimicking osseous metastasis, multiple myeloma, or tuberculosis. Obtain a high-quality core-needle biopsy, orient the biopsy corridor within the standard surgical approach, and demand immediate microbiological cultures and special histochemical stains for acid-fast bacilli and fungi. Discovering non-caseating granulomas transforms a presumed surgical catastrophe into a medically manageable systemic condition, sparing the patient an unnecessary ablative procedure. Furthermore, the moment musculoskeletal sarcoidosis is confirmed, immediately obtain a 12-lead electrocardiogram and cardiac consultation; silent myocardial granulomatous infiltration carries a fatal arrhythmogenic risk that dwarfs the musculoskeletal pathology.

Master Class Surgical Pearl: Musculoskeletal Sarcoidosis